PAK as a therapeutic target in gastric cancer

被引:27
|
作者
Li, Xiaodong
Liu, Funan
Li, Feng [1 ]
机构
[1] China Med Univ, Dept Cell Biol, Key Lab Cell Biol, Minist Publ Hlth, Shenyang 110001, Liaoning, Peoples R China
基金
中国国家自然科学基金;
关键词
P21-ACTIVATED KINASE PAK1; LIGHT-CHAIN KINASE; RHO-FAMILY; CYCLIN D1; COLORECTAL-CANCER; GENE-EXPRESSION; EXCHANGE FACTOR; DOWN-REGULATION; ARP2/3; COMPLEX; CELL-MIGRATION;
D O I
10.1517/14728221003642019
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Areas covered in this review: The complex regulation of PAKs through their upstream or downstream effectors in human cancers, especially in gastric cancer, are described and the identified inhibitors of PAKs are summarized. What the readers will gain: The structural differences and activation mechanisms between two subgroups of PAK are described. Both groups of PAKs play complicated and important roles in human gastric cancer, which indicated a possible way for us to identify the specific inhibitors targeting PAKs for gastric cancer. Take home message: PAKs play important roles in progression of many cancer types, the full mechanisms of PAKs in gastric cancer are still unclear. It seems there are different roles for two groups of PAKs in cancers. Group I PAKs play their functions mostly through their specific substrates, however, many binding partners that are independent of phosphorylation by group II PAKs were identified. Finding specific inhibitors of PAKs will help us discover the roles of PAKs and target these kinases in human gastric cancer.
引用
收藏
页码:419 / 433
页数:15
相关论文
共 50 条
  • [1] PAK1: A Therapeutic Target for Cancer Treatment
    Abdel-Magid, Ahmed F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (05): : 431 - 432
  • [2] PAK1 as a therapeutic target
    Kichina, Julia V.
    Goc, Anna
    Al-Husein, Belal
    Somanath, Payaningal R.
    Kandel, Eugene S.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (07) : 703 - 725
  • [3] PAK4 pathway as a potential therapeutic target in pancreatic cancer
    Thillai, Kiruthikah
    Sarker, Debashis
    Wells, Claire
    FUTURE ONCOLOGY, 2018, 14 (07) : 579 - 582
  • [4] cMET as a potential therapeutic target in gastric cancer
    Teng, Lisong
    Lu, Jun
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2013, 32 (06) : 1247 - 1254
  • [5] MerTK is a novel therapeutic target in gastric cancer
    Yi, Jun Ho
    Jang, Jiryeon
    Cho, Jeonghee
    Do, In-Gu
    Hong, Mineui
    Kim, Seung Tae
    Kim, Kyoung-Mee
    Lee, Sujin
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Kang, Won Ki
    Lim, Ho Yeong
    Lee, Jeeyun
    ONCOTARGET, 2017, 8 (57) : 96656 - 96667
  • [6] mTOR as a therapeutic target in patients with gastric cancer
    Al-Batran, Salah-Eddin
    Ducreux, Michel
    Ohtsu, Atsushi
    INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (03) : 491 - 496
  • [7] HIF in Gastric Cancer: Regulation and Therapeutic Target
    Li, Mengqing
    Li, Guan
    Yang, Xiaodong
    Yin, Weihua
    Lv, Guoqing
    Wang, Shubin
    MOLECULES, 2022, 27 (15):
  • [8] PAK2 as a therapeutic target in cancer: Mechanisms, challenges, and future perspectives
    Chen, Xin-Pan
    Yang, Zi-Tao
    Yang, Shang-Xin
    Li, En-Min
    Xie, Lei
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2025, 1880 (01):
  • [9] Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer
    Da-zhi Xu
    Qi-rong Geng
    Ying Tian
    Mu-yan Cai
    Xin-juan Fang
    You-qing Zhan
    Zhi-wei Zhou
    Wei Li
    Ying-bo Chen
    Xiao-wei Sun
    Yuan-xiang Guan
    Yuan-fang Li
    Tong-yu Lin
    BMC Cancer, 10
  • [10] Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer
    Xu, Da-zhi
    Geng, Qi-rong
    Tian, Ying
    Cai, Mu-yan
    Fang, Xin-juan
    Zhan, You-qing
    Zhou, Zhi-wei
    Li, Wei
    Chen, Ying-bo
    Sun, Xiao-wei
    Guan, Yuan-xiang
    Li, Yuan-fang
    Lin, Tong-yu
    BMC CANCER, 2010, 10